Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking

L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE

Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action? @RheumNow ABST0297 #ACR22 https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB

• Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients…

Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5

• Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As A…

Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp

• Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Resul…

New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML

Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5

Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8

• Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 T…